GLP-1 Basics: Appetite, Glucose, and Risk

GLP-1, short for glucagon-like peptide-1, is a hormone released by cells in the small intestine within minutes of eating. It belongs to a family of gut hormones called incretins, which link the act of eating to how the body handles the glucose that follows. GLP-1 is short-lived in circulation, broken down within a couple of minutes by an enzyme called DPP-4, which is part of why the drugs built around it are engineered to resist that breakdown so a single injection can act for days.

In plain terms, GLP-1 does three linked things after a meal. It tells the pancreas to release more insulin when blood glucose is elevated, which helps clear glucose from the blood. It slows the rate at which the stomach empties its contents into the small intestine, which spreads out glucose absorption instead of delivering it all at once. And it acts on appetite-regulating regions of the brain to increase the sense of fullness. Researchers describe these three effects together as the reason GLP-1 receptor agonist drugs can be useful for both type 2 diabetes and weight management: the drugs amplify an existing post-meal signaling pathway rather than introducing a mechanism the body has never encountered. [1]

The approved medicines in this drug class differ in target, schedule, and typical effect size. Semaglutide is marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management; both are once-weekly injections that act on the GLP-1 receptor alone. Liraglutide, sold as Victoza for diabetes and Saxenda for weight management, is chemically related but requires daily dosing and tends to produce smaller average weight change in trials. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management, activates both the GLP-1 receptor and a second incretin receptor (GIP), a dual-agonist design that in trials has produced larger average weight loss than single-receptor drugs.

Strong Human Evidence supports the efficacy of this drug class for weight reduction from large randomized, placebo-controlled trials. In the STEP 1 trial, adults with obesity or overweight who received semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group, which also received lifestyle counseling. [2] In the SURMOUNT-1 trial, tirzepatide at the 15 mg weekly dose produced a mean weight reduction of 20.9% at 72 weeks, compared with 3.1% for placebo. [3] These are randomized, double-blind trial results, which is a materially stronger form of evidence than the observational or open-label data that circulates more widely online.

Side effects are common and mostly dose-dependent. Nausea is reported by a large share of participants during dose escalation, and vomiting, diarrhea, and constipation also occur. For many people these symptoms are worst during the weeks around a dose increase and ease afterward, though 'usually improves' is not the same as 'always resolves,' and discontinuation is a reasonable outcome for people who do not tolerate the drug.

There is also a safety profile beyond the gastrointestinal tract that is documented directly in FDA-approved prescribing information. Gallbladder problems, including gallstones, occur more frequently in people taking GLP-1 drugs than in placebo groups in the same trials, and rapid weight loss itself independently raises gallstone risk, so the two effects can compound. Acute pancreatitis has also been reported in people using GLP-1 medicines, which is why the drug labels for this entire class carry a related warning. In 2026, an FDA review of adverse event reports also prompted label updates describing gastroparesis (severely delayed stomach emptying) as a rare but documented risk with long-term use, distinct from the ordinary, expected slowing of gastric emptying that is part of how the drugs work. [4] None of this means the drugs are unusually dangerous; it means the risks are specific, documented, and worth understanding rather than dismissing.

The label for Wegovy, like other drugs in this class, lists absolute contraindications: a personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2. These exist because semaglutide produced thyroid C-cell tumors in rodent studies; whether the same risk applies to humans has not been established, but regulators have kept the precaution given the clarity of the rodent finding. [5]

When people in online communities say 'research peptides' in the GLP-1 context, they typically mean semaglutide or tirzepatide obtained outside FDA-regulated manufacturing and pharmacy channels, through compounding pharmacies operating outside standard oversight, international vendors, or chemical suppliers marketing to researchers. The distinction that matters most is not paperwork; it is chain of custody. Whether the vial actually contains the labeled compound, at the labeled concentration, manufactured under controlled sterility and quality conditions, is unverifiable outside a lab. The FDA has issued a formal alert describing dosing errors and adverse events, some requiring hospitalization, tied to compounded semaglutide products, including cases where patients or providers miscalculated a milligram-to-unit conversion and administered five to ten times the intended dose. [6]

For anyone using a GLP-1 pathway compound outside clinical supervision, the honest framing is that it is an unsupervised pharmacological exposure with real, well-characterized risks. Reasonable risk-reduction steps include knowing exactly what is in a given product to the extent that is verifiable, avoiding rapid dose increases, and tracking symptoms in a way that would surface a developing problem early: unusual or persistent abdominal pain, repeated vomiting, or signs that could reflect pancreatitis or a gallbladder complication. Severe or persistent abdominal pain, or vomiting that does not resolve, is a reason for prompt medical evaluation, and it matters that any treating clinician be told exactly what was used.

Longer-term outcome data adds an important piece of context: this drug class appears to work best as a sustained intervention for a chronic driver of appetite and metabolic regulation, not a short course. In trial extension data, people who stopped semaglutide after achieving weight loss regained a substantial portion of it over the following year, which is consistent with the idea that these drugs manage an ongoing physiological process rather than resetting it permanently. [2] That is one reason clinicians and researchers describe the decision to start a GLP-1 drug as a long-horizon one.

One aspect of GLP-1 treatment that gets less attention than the number on the scale is body composition. Weight lost on these drugs includes both fat mass and lean (muscle) mass, and the proportion of lean mass lost can affect strength, metabolic rate, and how a person feels day to day. Resistance training and adequate dietary protein are commonly discussed strategies for preserving lean mass during pharmacologic weight loss, though there is not yet a large body of long-term outcome data quantifying exactly how much they offset lean mass loss in this specific drug class. That gap is worth being honest about: the mechanistic rationale is solid, but dedicated long-term trials are still limited.

It is worth being explicit about where the evidence base is thinner. Long-term data (beyond roughly two to three years of continuous use) is still accumulating, since these drugs have only been approved for weight management for a few years; questions about very long-term safety, effects across a full human lifespan of use, and outcomes in adolescents remain areas of active study rather than settled fact. Trial populations have also skewed toward people who could access and afford structured clinical trial participation, which is not necessarily representative of everyone using these drugs in practice, including through unregulated channels.

The evidence quality also differs notably between the drug class as a whole and any individual compound within it. Semaglutide and tirzepatide, the two most widely used agents, each have large randomized trial programs behind their approved indications. Newer investigational compounds working through similar or additional incretin pathways, including experimental triple-hormone-receptor agonists still in clinical development, do not yet have comparable trial volume or duration, and any claims about their relative benefit should be read as Early Human Evidence at best, not as an established finding equivalent to what exists for the approved drugs.

Taken together, the evidence base for this drug class is genuinely strong for weight and glycemic effects in regulated, monitored use, and considerably less certain the moment a compound's identity, purity, and dosing accuracy cannot be verified. Those are two different risk conversations, and conflating them is where a lot of the public discussion goes wrong.